

May 26, 2022

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth

Announcement of collaborative research agreement with Kidswell Bio Corporation

Chiome Bioscience Inc. concluded joint research agreement with Kidswell Bio Corporation. The collaborative research makes us join their ongoing research project to develop therapeutic antibody for cancer.

Our mission is to shine the light on unmet medical needs through our research project of drug discovery and development. This collaborative research will expect to merge our research functions and experiences with novel antibody drug discovery project. We will continue to discuss the extended collaboration scheme with Kidswell Bio in case our joint research make the progress pushing the project up to the therapeutic drug development stage.

<Information>

Kidswell Bio Corporation Release

[NEWS | Kidswell Bio Corporation](#)

【Inquiries】

Chiome Bioscience Inc. Investor Relations

E-mail : ir@chiome.co.jp